Pfizer (PFE) today: Court denies bid to block Novo–Metsera deal; Pfizer preps sweeter offer and leans on higher 2025 EPS outlook
A Delaware court denied Pfizer’s request to block Metsera from ending their merger deal in favor of Novo Nordisk’s higher bid. Pfizer plans to raise its offer after Novo’s proposal reached up to $10 billion. FTC staff warned Novo’s bid structure could violate pre-merger rules. Pfizer shares traded near $24.61 midday Thursday.